Search Blog
Categories
March 2019
M T W T F S S
« Feb    
 123
45678910
11121314151617
18192021222324
25262728293031

Tags

Tecogen to Attend the 31st Annual Roth Conference on March 19, 2019

By Tecogen Inc.

WALTHAM, MA / ACCESSWIRE / March 18, 2019 / Tecogen Inc. (NASDAQ: TGEN), a clean energy company providing ultra-efficient, clean, natural gas powered on-site power, heating and cooling equipment, is pleased to announce that the company will be attending the 31st Annual ROTH Conference held at The Ritz Carlton, Laguna Niguel in Orange County, CA. Benjamin Locke, Tecogen’s CEO will be available to meet with investors on Tuesday, March 19, 2019 between the hours of 7:00 a.m. and 4:00 p.m. Pacific Time.

The company’s presentation materials will be made available in the Investor Relations section of our website under Investor Relations.

This conference is for clients of ROTH and by invitation only. If you are interested in attending, please contact a ROTH Sales Representative at 800-678-9147. You can also e-mail registration@roth.com for more information.

About Tecogen

Tecogen Inc. designs, manufactures, sells, installs, and maintains high efficiency, ultra-clean, cogeneration products including natural gas engine-driven combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint.

In business for over 35 years, Tecogen has shipped more than 3,000 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com or contact us for a free Site Assessment.

Tecogen, InVerde e+, Ilios, Tecochill, Tecopower, Tecofrost and Ultera are registered or pending trademarks of Tecogen Inc.

Forward Looking Statements

This press release contains ”forward-looking statements” which may describe strategies, goals, outlooks or other non-historical matters, or projected revenues, income, returns or other financial measures, that may include words such as ”believe,” ”expect,” ”anticipate,” ”intend,” ”plan,” ”estimate,” ”project,” ”target,” ”potential,” ”will,” ”should,” ”could,” ”likely,” or ”may” and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements.

In addition to those factors described in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q under ”Risk Factors”, among the factors that could cause actual results to differ materially from past and projected future results are the following: fluctuations in demand for our products and services, competing technological developments, issues relating to research and development, the availability of incentives, rebates, and tax benefits relating to our products and services, changes in the regulatory environment relating to our products and services, integration of acquired business operations, and the ability to obtain financing on favorable terms to fund existing operations and anticipated growth.

Tecogen Media & Investor Relations Contact Information:

Benjamin Locke, CEO
P: (781) 466-6402
E: Benjamin.Locke@Tecogen.com

SOURCE: Tecogen Inc.

ReleaseID: 539382

Bearing Announces Proposed Repricing of Warrants

Corporate Logo

Vancouver, British Columbia–(Newsfile Corp. – March 18, 2019) – Bearing Lithium Corp. (TSXV: BRZ) (OTCQB: BLILF) (FSE: B6K2) (“Bearing” or the “Company“) announces that, subject to approval by the TSX Venture Exchange, it intends to amend the terms of a total of 4,565,000 outstanding share purchase warrants (the “Warrants“) issued pursuant to a private placement that closed in two tranches on August 8, 2019 and August 16, 2019. Each Warrant is currently exercisable for one common share of Bearing at an exercise price of $0.40 per share. If approved, the proposed amendment will reduce the exercise price of the Warrants to $0.31 per share.

About Bearing Lithium Corp.

Bearing Lithium Corp. is a lithium-focused mineral exploration and development company. Its primary asset is an 18% interest in the Maricunga Lithium Brine Project in Chile. The Maricunga Project represents one of the highest-grade lithium brine salars globally and the only pre-production project in Chile. Over US$30 million has been invested in the Maricunga Project to date and all expenditures through to the delivery of a Definitive Feasibility Study have been fully-funded by the earn-in joint-venture partner.

ON BEHALF OF THE BOARD

Signed “Jeremy Poirier”
Jeremy Poirier, President and CEO

FOR FURTHER INFORMATION PLEASE CONTACT:
Jeremy Poirier– President and CEO Bearing Lithium – Telephone: 1-604-262-8835

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward-looking statements.

The words “expect”, “target”, “estimate”, “may”, “will” and other similar expressions identify forward-looking statements. These forward-looking statements relate to, among other things, the proposed repricing of Bearing’s Warrants, the future prospects of the Maricunga Project. Forward-looking statements involve known and unknown risks, uncertainties and other factors which are beyond Bearing’s ability to predict or control and may cause Bearing’s actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, failure to obtain the TSX Venture Exchange approval for the proposed Warrant repricing; strategic, legal, planning and other risks, the impact of changes in, or to the enforcement of, laws, regulations and government practices, potential defects in title to the Maricunga Project that are not known as of the date hereof, the occurrence of unexpected financial obligations, fluctuations in the price of lithium and other commodities, fluctuations in the currency markets, changes in national and local government, legislation, taxation, controls, regulations and political or economic developments, risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding), risks related to operational matters and geotechnical issues, the success of future exploration and development activities, the occurrence of any labour unrest, the ability to accurately predict decommissioning and reclamation costs, the risk of budget and timing overruns, potential opposition to the Maricunga Project by local communities and the ability to secure construction financing. Such forward-looking statements are also based on a number of assumptions which may prove to be incorrect including changes in Maricunga Project parameters as plans continue to be evaluated as well as those factors disclosed in the Company’s documents filed from time to time with the securities regulators in the Provinces of British Columbia and Alberta. Accordingly, readers should not place undue reliance on forward-looking statements. Bearing undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein whether as a result of new information or future events or otherwise, except as may be required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43466

InterRent Announces March 2019 Distributions

By InterRent Real Estate Investment Trust

Not for distribution to United States newswire services or for dissemination in the United States

OTTAWA, ON / ACCESSWIRE / March 18, 2019 / InterRent Real Estate Investment Trust (TSX-IIP.UN) (“InterRent“) announced today that its distribution declared for the month of March 2019 is $0.024167 per Trust unit, equal to $0.29 per Trust unit on an annualized basis. Payment will be made on or about April 15, 2019 to unitholders of record on March 31, 2019.

About InterRent

InterRent REIT is a growth-oriented real estate investment trust engaged in increasing Unitholder value and creating a growing and sustainable distribution through the acquisition and ownership of multi-residential properties.

InterRent’s strategy is to expand its portfolio primarily within markets that have exhibited stable market vacancies, sufficient suites available to attain the critical mass necessary to implement an efficient portfolio management structure and, offer opportunities for accretive acquisitions.

InterRent’s primary objectives are to use the proven industry experience of the Trustees, Management and Operational Team to: (i) to grow both funds from operations per Unit and net asset value per Unit through investments in a diversified portfolio of multi-residential properties; (ii) to provide Unitholders with sustainable and growing cash distributions, payable monthly; and (iii) to maintain a conservative payout ratio and balance sheet.

For further information about InterRent please contact:

Mike McGahan
Chief Executive Officer
Tel: (613) 569-5699 Ext 244
Fax: (613) 569-5698
e-mail: mmcgahan@interrentreit.com

Brad Cutsey, CFA
President
Tel: (613) 569-5699 Ext 226
Fax: (613) 569-5698
e-mail: bcutsey@interrentreit.com

Curt Millar, CPA, CA
Chief Financial Officer
Tel: (613) 569-5699 Ext 233
Fax: (613) 569-5698
e-mail: cmillar@interrentreit.com

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: InterRent Real Estate Investment Trust

ReleaseID: 539369

KWG Resources Announces Closing of Another Tranche of Its Convertible Debenture Private Placement

Corporate Logo

Toronto, Ontario–(Newsfile Corp. – March 18, 2019) – KWG Resources Inc. (CSE: KWG) (CSE: KWG.A) (FSE: KW6) (“KWG” or the “Corporation“) is pleased to announce closing on March 15, 2019 of another tranche of its private placement (the “Private Placement“) convertible debentures. This tranche was comprised of an aggregate of $775,647.58 of debentures. The debentures are convertible at the option of KWG into units (each a “Unit“) with a deemed value of $21 per unit. Each subscriber received an option to acquire an equal amount of additional debentures at any time within four (4) months from closing.

Each Unit is comprised of four (4) KWG.A multiple voting shares and four (4) multiple voting share purchase warrants, with each such warrant enabling its holder to acquire one further KWG.A multiple voting share from treasury upon payment of $7.50 at any time on or before December 15, 2019. The debentures bear interest at a rate of 12% per annum, accruing daily, compounding annually and payable at the earlier of maturity, redemption or conversion, in KWG.A multiple voting shares from treasury at their volume-weighted average price (“VWAP“) for the ten trading days prior to payment. The debentures secure repayment of the principal, plus interest earned thereon to the date of payment, plus a bonus of 20% of the original principal amount payable immediately following issuance of the debenture by the issuance of Units with a deemed value of $21 per Unit. At any time and from time to time, KWG will have the right to redeem the debentures in whole or in part by payment in cash, or convert the debentures in whole or in part into Units.

The following officers and directors of the Corporation (collectively, the “Insiders“) participated in the Private Placement for an aggregate of $560,207.58 of debentures plus 5,333 Units representing the bonus of 20% of the original principal amount, with the Units being comprised of an aggregate of 21,332 multiple voting shares and 21,332 warrants representing the equivalent of 1.18% of the Corporation’s issued and outstanding subordinate voting shares (calculated on the basis of conversion of the multiple voting shares into subordinate voting shares on a ratio of 300:1) on a partly diluted basis following closing of the Private Placement:

Name and Position with the Corporation No. of Subordinate Voting Shares held (and %) prior to Private Placement
No. of Subordinate Voting Shares issued under the Private Placement and issuable upon exercise of warrants (and %) No. of Subordinate Voting Shares held (and % ) following completion of Private Placement
Frank Smeenk
Director and Officer
27,573,846
(2.56%)
7,884,000
(44.50%)
31,515,846
(2.90%)
Douglas Flett
Director
5,685,000
(0.54%)
1,096,800
(6.19%)
6,233,400
(0.57%)
Thomas Masters
Officer
7,054,371
(0.65%)
1,977,600
(9.47%)
7,893,171
(0.73%)
Bruce Hodgman
Officer
2,647,862
(0.24%)
1,370,400
(7.73%)
3,333,062
(0.30%)
Donald Sheldon
Director and Officer
3,930,357
(0.36%)
770,400
(4.35%)
4,315,557
(0.40%)
Total: 46,891,436
(4.35%)
12,799,200
(72.24%)
53,291,036
(4.90%)

In the event that KWG exercises its right to convert the principal of all of these debentures, the Insiders’ ownership of KWG shares would increase as follows:

Name and Position with the Corporation No. of Subordinate Voting Shares held (and % ) following completion of Private Placement No. of Subordinate Voting Shares issued on conversion of principal and issuable upon exercise of warrants (and %) No. of Subordinate Voting Shares held (and % ) following completion of Private Placement and conversion of principal
Frank Smeenk
Director and Officer
31,515,846
(2.90%)
39,427,200
(44.48%)
51,229,446
(4.53%)
Douglas Flett
Director
6,233,400
(0.57%)
5,484,000
(6.19%)
8,975,400
(0.79%)
Thomas Masters
Officer
7,893,171
(0.73%)
8,392,800
(9.47%)
12,089,571
(1.08%)
Bruce Hodgman
Officer
3,333,062
(0.30%)
6,856,800
(7.74%)
6,761,462
(0.60%)
Donald Sheldon
Director and Officer
4,315,557
(0.40%)
3,856,800
(4.35%)
6,243,957
(0.55%)
Total: 53,291,036
(4.90%)
64,017,600
(72.23%)
85,299,836
(7.55%)

The foregoing does not include any consideration of shares issuable for interest as the exchange rate cannot be calculated at this time as the amount of interest will depend on the length of time the debentures are outstanding and the number of shares issuable is based on the VWAP for the 10 trading days prior to payment. As well, the foregoing does not include any consideration of the options to acquire additional debentures; however, if all such options were to be exercised the same numbers of shares and warrants would be issuable for the debenture premium and the conversion of the principal would result in the same numbers of shares and warrants being issued as described above.

The debentures were paid for by some subscribers by payment of cash and by other subscribers by settlement of bona fide debt. The cash proceeds received by the Corporation from the sale of the debentures will be used for the costs and fees associated with this Private Placement and for general corporate overhead expenses including repaying current debt. The working capital deficiency and balance sheet of the Corporation will be improved, which should facilitate future financings or other transactions.

All of the securities to be issued pursuant to this Private Placement are subject to a four (4) month hold period.

The Private Placement, in part, is a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“) as Insiders purchased debentures. A formal valuation was not required under MI 61-101 because the Corporation is not listed on any of the stock exchanges specified in MI 61-101. Minority shareholder approval was also not required as the fair market value of the consideration for the transaction involving the Insiders does not exceed 25 percent of the Corporation’s capitalization as of the date hereof, which is approximately $10 million. The directors participating to the Private Placement declared and disclosed their interest and did not vote on the matter. The directors who did not participate in the Private Placement approved the Private Placement.

Given the uncertainty as to whether Insiders would participate in the Private Placement, and to what extent, and the demands of creditors, the Corporation has not had the opportunity to announce this related party transaction 21 days in advance of closing.

About KWG:

KWG is the Operator of the Black Horse Joint Venture (‘JV’) after acquiring a vested 50% interest through Bold Ventures Inc (‘Bold’) from Fancamp Exploration Ltd (‘Fancamp’). KWG funds all JV exploration expenditures and Bold is carried for a 20% interest in KWG’s interest.

KWG also owns 100% of Canada Chrome Corporation which has staked claims and conducted a surveying and soil testing program, originally for the engineering and construction of a railroad to the Ring of Fire from Aroland, Ontario.

KWG subsequently acquired intellectual property interests, including a method for the direct reduction of chromite to metalized iron and chrome using natural gas and an accelerant. KWG subsidiary, Muketi Metallurgical LP, has received a patent for the direct reduction method in Canada, South Africa and Kazakhstan and is prosecuting remaining patent applications in India, Indonesia, Japan, South Korea, Turkey and the USA. It has also received a USA patent for production of low carbon chromium iron alloys and a corresponding Canadian patent application is expected to issue soon.

For further information, please contact:
Bruce Hodgman, Vice-President: 416-642-3575 ~ info@kwgresources.com

Forward-Looking Statements: Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and KWG disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Accordingly, undue reliance should not be put on such.

This news release does not constitute an offer to sell or solicitation of an offer to buy any securities that may be described herein.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43473

Ozop Surgical Corp Provides Corporate Update and Outlook for 2019

By Ozop Surgical Corp.

WEST PALM BEACH, FL / ACCESSWIRE / March 18, 2019 / Ozop Surgical Corp. (OTCQB: OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery, today released the following corporate update and outlook for 2019 from Michael Chermak, Chief Executive Officer and Chairman.

As a way of introduction; Ozop Surgical Corp invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.

I began this endeavor a few years ago spurred by the convergence of several factors driving the healthcare industry. First, rising costs showing little sign of slowing down and second, demographics portend increased demand as demand rises exponentially with age. Concurrently, the average operating margin for hospitals is 2.8%1, while nearly 44% of rural hospitals are losing money2. This reality places great stress on hospitals while reimbursement schemes are increasingly placing the financial risk on provider organizations. We believe that strategies that can measurably reduce cost in the healthcare industry without sacrificing patient care or outcomes will be rewarded and, in some cases, may be critical to the financial viability of provider organizations. Concurrent to these trends, surgery is inexorably moving toward minimally invasive surgery (MIS). Witness the impact over the last 20 years in general surgery (gall bladder, appendix) cardiothoracic (stents, valve replacement and bypass procedures) and orthopedics (knees, shoulders and hips). The impact of MIS is well documented including lower cost, fewer complications, faster recovery and less pain. Spine surgery is lagging for the simple reality that most procedures call for rather large objects (interbodies) to be placed inside the human body. A large object historically called for a large opening. But what if we could place an object through a small opening, that can be enlarged after inserted? This is routinely done in millions of patients per year using medical quality balloons, whether it is for the opening arteries or the fixing of broken bones. Fortunately for us we were able to secure a compelling IP portfolio created by a brilliant neurosurgeon to repurpose existing technologies, material and procedures, to solve a significant and costly problem – spinal fusion. This update lays out or most recent past milestones, while laying out our 2019 operating objectives.

Our corporate strategy revolves around combining spinal access and interbody implantation using a less invasive approach than what is currently available to spine surgeons. The goal is to combine single use sterile packed implants with disposable approach instruments such as endoscopes, shavers, and other ancillary prep instruments. The use of disposable instrumentation which is sterile packed is becoming the standard due to the ease of use with disposable kits and concerns about resterilization, especially in the Ambulatory Surgical Center (ASC) setting. Each kit will be specific to the procedure, eliminating waste and allowing for a more efficient procedure. Performing the whole procedure through a small working channel has the potential to decrease operative time and the risk of infection while allowing for a faster return to activities of daily living. The potential cost savings are substantial and measurable.

Key events 2018

  • Went public – after years as an EU based company we redomiciled in Delaware in February of 2018, and subsequently acquired Spinus LLC. This gave us exclusive licensing rights to a rich IP portfolio as well as an FDA approved spine product line. In April we merged into a public entity and changed our symbol to OZSC.
  • During 2018, we expanded our management team and engaged advisors. We added Thomas McLeer as Chief Operating Officer. Tom has over 30 years of experience in the spine industry at the senior operating level. We also added advisors in public markets and investment relations.
  • We began development of an enhanced expandable ALIF (anterior lumbar interbody fusion) implant with initial designs and prototypes completed. This product is easier to insert and use than other competitive products. We will complete design and testing in the first half of 2019 and anticipate FDA approval in the second half of 2019.
  • In late 2018 we began the process of ordering a variety of spine fusion sets in order to evaluate any needed enhancements and begin surgeon evaluations. These sets have begun to arrive in Q1 2019, and are being strategically placed and should begin to be used in surgeries during Q2 2019. These sets include the traditional ALIF instruments needed for such surgeries.
  • In December 2018 we successfully uplisted to the OTCQB on OTC Markets. This was an important step for us as a ‘34 Act, fully reporting public company.

Key planned events 2019

  • As we continue to evaluate our IP portfolio, we plan to broaden the scope of our claims as it relates to balloon technology for fusion and motion preservation in the disc.
  • Initiate IR program to build liquidity in our stock – we will kick off our investment relations program to build investor and market awareness of our company.
  • Upcoming trade shows/presentations – we plan to present our company at select and targeted venues, starting with the MicroCap conference April 1 and 2 in New York City. We believe it is important to raise our visibility with brokers, investment bankers and market makers. Other events are in the planning stages and will be announced as they come up.
  • Begin core spine fusion sales, including the new expandable ALIF and scale this program using our existing surgeon/distributor relationships. This includes evaluating our implant offering to insure it meets surgeon needs and upgrading the instrumentation as needed. Depending on the complexity of the changes we will file for additional FDA 510K approvals as needed.
  • Determine focus and strategy for spine scope program.
  • Build out our Clinical Advisory Board with nationally recognized spine surgeons.
  • Independent board of directors, in the future, we will build our board of directors by adding independent members with critical experience in the Nasdaq uplist process, deep experience in public markets, and senior level experience in our industry. Uplist to Nasdaq is our ultimate goal to enable us to access the institutional investor sector and further enhance the liquidity of our stock.

Ongoing Balloon Lumbar Interbody Fusion (“BLIF”) Development (2019/2020)

Broad milestones for the development of our BLIF technology include:

  • Ongoing filing of additional IP as development continues
  • Establish an experienced team of surgeons and industry experts to develop the approach, delivery, and the implant for the BLIF system
  • Finalize the list of appropriate polymers for the balloon and the interbody implant and begin testing
  • Develop prototypes and conduct testing and labs as needed to validate the concept from incision to closure
  • Complete all necessary testing for FDA submission and identify appropriate substantially equivalent devices.
  • Upon approval we will build sets, finalize a robust training regimen, and begin our alpha launch at key centers.

In summary, we are happy with our accomplishments to date and realize we have a lot of work ahead of us to achieve our goals and objectives for 2019 and beyond. I thank all of our shareholders and investors for the confidence they have shown in our Company and I look forward to not only growing our shareholder base and other relationships, but to also make a significant impact on those suffering back pain as well as on the healthcare industry as a whole.

About Ozop Surgical Corp.

Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.

Safe Harbor Statement

Investor Relations:
Ted Haberfield
President
MZ Group – MZ North America
(760) 755-2716
thaberfield@mzgroup.us
www.mzgroup.us

(1) Beckers Hospital Review
(2) National Rural Health Association 2018 Rural Health Policy Institute

SOURCE: Ozop Surgical Corp.

ReleaseID: 539339

Sterna Biologicals Holds Scientific Advisory Board Meeting at 14th Congress of ECCO to Advance Phase IIb Clinical Development Program of SB012 in Ulcerative Colitis

By sterna biologicals GmbH & Co. KG

– Meeting included international key opinion leaders
– Input provided on SB012 development plan and phase IIb trial protocol

MARBURG, GERMANY / ACCESSWIRE / March 18, 2019 / Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the company held a Scientific Advisory Board (SAB) meeting to evaluate the phase IIb clinical development program for SB012 in ulcerative colitis (UC). SB012 is based on sterna’s proprietary and patent-protected active pharmaceutical ingredient, hgd40, a DNAzyme and first-in-class GATA-3 antagonist. The SAB meeting was held on March 7, 2019 during the 14th Congress of ECCO (European Crohn’s and Colitis Organisation) in Copenhagen, Denmark.

At the SAB meeting, the clinical development program for SB012 in ulcerative colitis, particularly the design of the phase IIb study was discussed and further solidified. Prof. Dr. med. Harald Renz, Co-founder and chairman of sterna biologicals and member of the Company’s Scientific Advisory Board, commented: “We have seen promising phase IIa clinical results with SB012 and are now advancing this program into the next stage of clinical development. Our Scientific Advisory Board has provided us with valuable input on the design of our phase IIb study with SB012, which we are now incorporating into the trial protocol in preparation for meetings with regulatory authorities, which we expect to hold later this year.”

ABOUT SB012

SB012, a DNAzyme and first-in-class GATA-3 antagonist was tested with an enema formulation of hgd40. For further clinical development (i.e. phase IIb and phase III) and commercialization, an oral formulation of SB012 is being developed.

GATA-3 is the master transcription factor regulating Th2-driven inflammatory diseases such as ulcerative colitis, atopic dermatitis, eCOPD and asthma. By inhibiting GATA-3, the expression of downstream cytokines, interleukin IL-4, IL-5, and IL-13, which cause inflammation, is down regulated. In pre-clinical and clinical development, SB012 was found to be well tolerated with first signs of efficacy. DNAzymes are single-stranded DNA molecules comprising a central catalytic domain flanked by two binding domains. The binding domains attach to a specific sequence of targeted mRNA, such as GATA-3 mRNA in the case of SB012. After binding to the target, the catalytic domain then cleaves the mRNA, thereby inhibiting relevant downstream cytokine expression.

PHASEIIa RESULTS – ULCERATIVE COLITIS

The SECURE study was a prospective, multi-center, randomized, double-blind, placebo-controlled trial that enrolled a total of 20 patients with moderate to severe ulcerative colitis. SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. At day 28, there was a statistically significant improvement in the Mayo Score in the SB012 group compared with the placebo group (p=0.04). Clinical remission, clinical response, mucosal healing rates and endoscopic response at days 28 and 56 were also assessed.

ABOUT STERNA BIOLOGICALS

Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase II development.

For more information, please visit www.sterna-biologicals.com.

CONTACT

Christian Pangratz
Chief Executive Officer

sterna biologicals GmbH & Co. KG
Bismarckstrasse 7
35037 Marburg

c.pangratz@sterna-biologicals.com
Tel.: +49 (0)6421.98 30 05 0

For media inquiries:

Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22

SOURCE: sterna biologicals GmbH & Co. KG

ReleaseID: 539367

The Blockchain Payment Platform PayDex Makes a Breakthrough in the Bear Market

By PayDex

NEW YORK, NY / ACCESSWIRE / March 19, 2019 / For most blockchain players, 2018 is long and difficult. The prices of mainstream currencies such as Bitcoin, Ethereum, and EOS have once again fallen from the peak to the bottom. Some unsustainable and finally shattered projects have once again prompted the public to question the prospects of blockchain technology.

Therefore, 2019 is an extremely important year. Cryptocurrencies de-bubble, blockchain technology “de-deification”, team members of major projects are in need of such relatively quiet moments to set the future direction of their projects, but this is not so simple.

For the members of the Vtoken public chain and its founding team, the moment they waited for finally came.

Prospects of “blockchain + payment” are unlimited

In recent years, the popularity of mobile devices and the development of the Internet have promoted the rapid development of the mobile payment industry. The current society is undergoing a full evolution of the cashless society. According to authoritative statistics, by 2022, the transaction value of mobile payment applications is expected to reach nearly 14 trillion US dollars (about 96 trillion yuan), and the industry is in a stage of rapid development.

In this round of mobile payment high-speed express, the rapid development of China’s Alipay has made Alibaba one of the top ten companies in the world. The prospects and potential of mobile payments are self-evident.

However, the current Internet is a centralized network. Despite the rise of payment instruments such as Alipay, there are still problems of inefficiency, high centralization risk, and high transaction costs.

PayDex is relying on advanced blockchain technology to reinvent mobile payments with its decentralization, information point-to-point transmission, and information that cannot be tampered with.

Technology-based

A project can’t land if it only has the imagination, the most fundamental thing is to rely on advanced and solid technology.

Paydex (Vpayment) is an online payment channel based on the Vtoken public chain, while Vtoken was developed by the original Ripple founding team. Vtoken’s underlying protocol combines Ripple, Stellar and graphene underlying technology. It is a banking-like system with the same trading gateway like Stellar between fiat and cryptocurrencies, with efficient and stable TPS (transaction speed). Its transaction processing speed is even higher than EOS.

Paydex (Vpayment) is developed by the original team of the founding team. It will provide payment for all cryptocurrencies including BTC, ETH, Vtoken, VPC, USDT, VRT, YEC, EOS, LTC and VUST for users and Vtoken families around the world. In addition to supporting the circulation and payment of all cryptocurrencies assets in Vtoken, it also provides cryptocurrencies settlement for various countries in the world, allowing various cryptocurrencies to be easily exchanged and bridging the global currency exchange.

The application is King

Simply, Paydex (V payment) has the following six advantages in practical applications:

First, using the Proof of Burn consensus mechanism in Vtoken core technology, through the super node, each user can easily and fairly query in the chain browser to achieve asset transparency and reject false accounts.

Second, each user is a clearing gateway, which can realize cross-border global currency global distributed clearing. Each clearing gateway is an acceptor, and all can be profitable through circulation replacement.

Third, to provide merchants with a payment SDK, you can implement QR code collection on the merchant’s website and return the collection result and automatic delivery, which can link all the application scenarios of the global mall to pay.

Fourth, the launch of the mobile wallet APP can realize the scan code payment and NFC payment function, realize the aggregate payment, and have payment experience of Alipay and WeChat payment.

Fifth, limited real-name system to ensure the security of funds while providing sufficient anonymity.

Sixth, the global payment results are confirmed in real time, no network congestion.

For consumers, Paydex (V payment) can consume all digital assets in affiliate merchants and online malls, saving money and making more money. For merchants, Paydex can be used to serve hundreds of millions of high-quality cryptocurrencies holders worldwide.

For the average user, you can also apply for a dealer to earn the price difference. For cross-border e-commerce providers with cross-border payment requirements, it is easy to settle the national currency through PayDex (V payment) exchange settlement, solve the problem of payment and payment in all sensitive areas, and make goods easily flow around the world and create more revenue.

Profit sharing

After a long period of technical development verification, Paydex (V payment) will be officially launched before May 2019. In addition to VTOEKN’s own currency appreciation, Paydex (V payment) promises to pay dividends to Vtoken families who support the v-chain, guarantee the interests of each ecological member, and build a long-term stability. the ecology of development.

Only when the public tends to be rational, those projects that have been quietly cultivated and valuable can be discovered. At present, Vtoken has achieved effective results in Southeast Asia. With Paydex (V payment) officially launched, Vtoken’s complete ecological ring will be fully opened. As time progresses, I believe that Paydex will be able to stand out from the crowd and create a convenient and efficient payment method for users around the world.

As its founder Mark Minor said: ‘We defend the spirit of decentralization like bitcoin, let circulation generate value, and create a new financial model!’

Contact:

Bibei778@gmail.com

SOURCE: PayDex

ReleaseID: 539333

David Simonini Unveils New South Carolina Development

By The Simonini Group

As the Director of Creative Consulting for the Simonini Group, David Simonini combines authentic architecture and innovation to the Carolinas

LANCASTER, SC / ACCESSWIRE / March 18, 2019 / David Simonini is pleased to announce a highly anticipated three-building development in Lancaster, South Carolina. The ongoing project will consist of 72 apartments in total (36 2/BR and 36 3/BR) with each building being 3 stories high. The subject property is on 5.52 acres of entitled land and will have a common clubhouse and walkways.

President Trump’s opportunity zone incentive is a community investment tool established by Congress to cultivate change in low income urban and rural communities nationwide. As a federal approved opportunity zone, the property will also be subject to significant tax benefits, offering investors a competitive advantage.

Ultimately, the 72 units will contribute to the growth of the area and to accommodate low-income housing.

For more information on the South Carolina development or the Simonini Group please visit http://www.simoninigroup.com.

For more information on President Trump’s opportunity zones visit https://www.cnbc.com/2018/10/19/trump-opportunity-zones-popular-with-investors-but-might-offer-less-for-voters.html

About David Simonini

The Simonini Group specializes in acquisitions, project management, implementation, and custom home building. They have constructed some of Charlotte’s most exclusive residences and have received both local and national awards. As an advisor and a consultant, David Simonini has designed and built over 500 town homes and 1,000 custom homes throughout his extensive career and has collaborated with the visionary Miami-based architect and planner, Andres Duany.

With over 35 years of professional experience, the company is comprised of high performing individuals who take pride in their ability to create homes that will stand the test of time.

Contact Information:

David Simonini
7804 Fairview Road
Charlotte, NC 28226
david@simoninigroup.com

SOURCE: The Simonini Group

ReleaseID: 539371

Uptick Newswire Hosts Canbiola, Inc. on The Stock Day Podcast to Discuss Growth Potential in 2019

By Uptick Newswire

PHOENIX, AZ / ACCESSWIRE / March 18, 2019 / Uptick Newswire Stock Day Podcast welcomed Canbiola, Inc.(CANB) (”the Company”), a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Executive Vice President of Domestic and International Sales, Andrew W. Holtmeyer, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Holtmeyer what inspired the Company to move from the cannabis space to the medical device space. Holtmeyer stated, ”We pride ourselves on always being at the cutting edge of trying to help people heal themselves in an integrative form without opioids.”. He further explained that the Company currently offers its clinical CBD products directly to physicians, but is also working on rolling out a national retail line. ”We are always looking for alternatives to pain.”, added Holtmeyer.

Jolly then asked about the Sam PRO 2.0 unit and how it compares to other devices on the market. ”The Sams PRO 2.0 unit is the only FDA cleared, wearable, low-intensity, ultrasound device of its kind.”, explained Holtmeyer. This device can be worn for up to four hours and is highly effective in speeding up recovery and treating pain. This technology is exceptionally unique as it is able to integrate CBD, which further increases its effectiveness in pain and as an anti-inflammatory.

Holtmeyer then explained that the Company has expanded into other areas of pain relief and technology in an effort to discover better treatment alternatives that allow individuals in need of healing to avoid opioids.

Jolly then asked about the Company’s recent acquisitions. Holtmeyer explained that the Company’s most recent acquisition will allow them to extend their current product line, while also shortening their time frame for production.

”Canbiola is not just your ordinary CBD company. We look to differentiate ourselves on a daily basis,” stated Holtmeyer. He added that the Company strives to surround itself with individuals that are on the cutting edge of this industry. Holtmeyer also says that the company was recently registered and is Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD).

To close the interview, Holtmeyer shared that the Company is looking forward to a robust year and expects their clinical line to continue to expand. Holtmeyer also looks forward to the development and launch of their retail line with a positive outlook for its reception on the market.

To hear Andrew Holtmeyer’s entire interview, follow the link to the podcast here: https://upticknewswire.com/vp-of-sales-andy-holtmeyer-of-canbiola-inc-otcqb-canb/

Investors Hangout is a proud sponsor of ”Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/

About Canbiola, Inc.:

Canbiola, Inc. is a public company trading under symbol CANB.

Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

CONTACT INFORMATION:

Canbiola Investor Relations

Email: IR@canbiola.com

Phone: (516) 595-9544

website: http://www.canbiola.com

Follow us on Twitter and Facebook

About Uptick Newswire and the ”Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its ”Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network ”Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

602-441-3474

https://upticknewswire.com/

SOURCE: Uptick Newswire

ReleaseID: 539370

City View Green Holdings Inc. Appoints Alcohol Beverage Industry Veteran as New CEO

Corporate Logo

Toronto, Ontario–(Newsfile Corp. – March 18, 2019) – City View Green Holdings Inc. (formerly Icon Exploration Inc.) (the “Company” or “City View Green”) trading through the facilities of the Canadian Securities Exchange (“CSE“) under the symbol “CVGR” is pleased to announce that Mr. Ian MacDonald has accepted the position as CEO effective immediately. Mr. MacDonald is a well-respected and proven leader with a distinguished career in the international alcohol beverage industry and has a solid reputation of creating and growing both profitable and sustainable companies. With a strong foundation in sales, marketing and executive management and over 30 years experience in the highly regulated beverage alcohol space, Ian has repeatedly transformed companies into award winning, innovative and industry leading organizations. Mr. MacDonald began his career at Labatt Breweries where he first developed his passion for the beverage alcohol industry. After numerous advancements within the commercial departments within Labatt, Ian went on to pursue other opportunities within the brewing industry including Lakeport Brewing Corporation, where Mr. MacDonald was instrumental in pioneering the discount brewing segment and transforming Lakeport from a company on the verge of insolvency into a profitable and award-winning business. Ian has also created and led successful turnaround strategies for other notable businesses including the relaunched Steelback Brewery, Nickel Brook Brewing Company and Cott Beverages where Mr. MacDonald led Cott into the production of alcohol-based beverages and ultimately established Cott as the leader in the alcohol beverage manufacturing space. Ian also held the top position for Carib Brewery in Trinidad and Tobago where Mr. MacDonald led the company to record setting profitability through implementing significant cost savings and efficiency initiatives. Mr. MacDonald has also lent his talents and expertise to several other notable companies on a consultancy basis. “Being involved with the great team of people here at City View Green in this new and revolutionary cannabis industry is incredibly exciting,” stated Mr. MacDonald.

Mr. MacDonald added, “Before accepting this critical role, I insisted I spend some time within the organization first to ensure this company is equipped to deliver the success I strive for. I don’t take this responsibility lightly and I am committed to delivering on the commitments I make. After meeting the incredible team at City View Green, vetting their business model and assessing their ability to differentiate themselves in the cannabis space, it was an easy decision to join this great Company.”

When asked what sets City View Green apart from everyone else in the cannabis space, Ian explained, “City View Green has arguably the best team in the business. Our master grower is a former founder of Weed MD, our extraction specialist is one of the most experienced extraction professionals in North America, our QA person has actual cannabis experience which is rare in a market that is still in its infancy. It’s the team that will set us apart from everyone else. We also have a fully integrated business model that includes ownership in a retail cannabis group, Budd Hutt Inc., which will ensure a direct route to retail once we are fully operational. The vision for the company is forward looking and holds the opportunity for international partnerships and expansion.”

The Board of Directors of City View Green would like to announce that Mr. Rob Fia will be appointed as President and will step down as CEO of City View Green. The Board would like thank Mr. Fia for his tireless efforts quarterbacking City View Green to this point and expanding the Company from concept to realization by adding talent and vertical business opportunities along with his expert knowledge of go public transactions. Mr. Fia, commented, “I would like to welcome Mr. MacDonald as CEO of City View Green. I have no doubt he will make this one of the most successful cannabis companies in the industry. Ian knows how to build great teams and how to win in a highly regulated industry. This individual is an incredible strategist with a global perspective. We can’t wait to share the great initiatives that Ian and the team are currently working on with our shareholders. Having him in early in a consultancy role to assess if the opportunity was right for him and his incredible desire to deliver results has enabled him to hit the ground running from day one. Ian rounds out our creative hard-working talent in growing, extraction and retail and I look forward to working closely with Ian and the City View Green team as we expand our business.”

City View Green has been structured to be a vertically integrated cannabis company focused on seed to retail. Upon receipt of its Cannabis Act licence, City View Green will incorporate growing, extraction, production and retail at their Brantford, Ontario facility. It is our intention that City View Green will grow exceptional quality cannabis and produce high quality extracts. Once legalized, it is our expectation that City View Green will produce high quality edible products, distillates and water-soluble products for the beverage market. In addition, City View Green owns a 19.9% stake in Budd Hutt Inc (“Budd Hutt”). Budd Hutt is a retail focused Cannabis company with access to licenses in Alberta and other retail opportunities across Canada. We expect that Budd Hutt will secure shelf space and distribution opportunities for City View Green’s products. City View’s Future is Green. Follow the Green. For more information visit www.cityviewgreen.ca.

For further information contact:

City View Green Holdings Inc.

Ian MacDonald, CEO

Email: ian@cityviewgreen.ca

Rob Fia, President & Director

Email: rob@cityviewgreen.ca

Neither the Canadian Securities Exchange nor its regulations services accept responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

This press release contains forward-looking statements such as international business opportunities, future cannabis products and other business initiatives related to expansion of the Company and information that are based on the beliefs of management and reflect the Company’s current expectations. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/43472